Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer

被引:8
|
作者
Fanelli, Mara [1 ]
Camperchioli, Alessia [2 ]
Petrella, Lella [1 ]
Petrillo, Marco [3 ,4 ]
Baranello, Cinzia [1 ,5 ]
Baccaro, Pina [1 ]
Paolillo, Carmela [6 ,7 ]
Capoluongo, Ettore [1 ,6 ,7 ]
Scambia, Giovanni [1 ,3 ,4 ]
机构
[1] Jean Paul 2nd Res Fdn, Lab Mol Oncol, Campobasso, Italy
[2] Molipharma Srl, Res Lab, Campobasso, Italy
[3] Catholic Univ, Dept Obstet & Gynecol, Rome, Italy
[4] Fdn Gemelli Hosp, Rome, Italy
[5] Danbury Hosp, Res Inst, Danbury, CT USA
[6] Catholic Univ, Inst Biochem & Clin Biochem, Lab Clin Mol & Personalized Diagnost, Rome, Italy
[7] Fdn Gemelli Hosp, Rome, Italy
来源
关键词
Integrins; NCK2; Ovarian cancer; TUMOR ANGIOGENESIS; EXPRESSION; SURVIVAL; ADHESION; INTEGRINS; VEGF;
D O I
10.5301/ijbm.5000264
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: In this study we investigated the function of the non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) and its correlation with ITGB1 and ITGB4 integrins in driving ovarian cancer (OvCa) aggressiveness. We also evaluated whether NCK2 may influence prognosis in OvCa patients. Methods: Nanofluidic technology was used to analyze expression of NCK2 in 332 OvCa patients. To evaluate mRNA expression of NCK2, integrins and VEGFA in OvCa cell lines, qRT-PCR was performed. Stable NCK2 overexpression was obtained in OVCAR3. qRT-PCR and Western blot were performed to evaluate expression changes of VEGFA, vimentin, ITGB1, ITGB4, MMP2 and MMP9 under normoxia and hypoxia conditions. Coimmunoprecipitation (Co-IP) was performed in the A2780 cell line to study the interaction between NCK2 and proteins of interest. To investigate whether NCK2 can influence anchorage-independent growth, a soft agar assay was completed. Transwell invasion assay was performed on stable-transfected OVCAR-3 cell lines. Results: Nanofluidic data showed NCK2 can play an important role as a factor promoting tumor aggressiveness and survival in OvCa. This role was also linked to the behaviors of ITGB1 and ITGB4. Moreover, in cells overexpressing NCK2, the expression of vimentin, MMP2, MMP9, VEGFA and ITGB1, but not of ITGB4 was induced by hypoxia. Co-IP showed that NCK2 can directly bind ITGB1, but not VEGFA. NCK2 may be involved in mediating cell-extracellular matrix interactions in OvCa cells by influencing tumor aggressiveness. Conclusions: This study provides evidence of a possible role of NCK2 as biomarker of OvCa progression.
引用
收藏
页码:124 / 131
页数:8
相关论文
共 50 条
  • [41] Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways
    Singel, Stina M.
    Batten, Kimberly
    Cornelius, Crystal
    Jia, Gaoxiang
    Fasciani, Gail
    Barron, Summer L.
    Wright, Woodring E.
    Shay, Jerry W.
    BREAST CANCER RESEARCH, 2014, 16 (02):
  • [42] Protein Tyrosine Phosphatase N2 (PTPN2) Knock-Down Suppresses Epithelial Ion Transport By Promoting Epidermal Growth Factor (EGF) -Induced EGF-Receptor (EGFR) and Phosphatidylinositol 3′-Kinase (PI3-K) Activation
    Scharl, Michael
    Rudenko, Ivan
    Barrett, Kim E.
    McCole, Declan F.
    GASTROENTEROLOGY, 2009, 136 (05) : A710 - A710
  • [43] DYRK2, a Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase Gene Expression Can Be a Powerful Prognostic and Predictive Factor in Non-Small Cell Lung Cancer.
    Yamashita, S.
    Chujo, M.
    Anami, K.
    Miyawaki, M.
    Yamamoto, S.
    Kawahara, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [44] The mechanism of L1 cell adhesion molecule interacting with protein tyrosine kinase 2 to regulate the focal adhesion kinase-growth factor receptor-bound protein 2-son of sevenless-rat sarcoma pathway in the identification and treatment of type I high-risk endometrial cancer
    He, Wei
    Liu, Wei
    Liu, Xiumei
    Tan, Wenhua
    CYTOJOURNAL, 2024, 21
  • [45] Vascular Endothelial Growth Factor (VEGF) Receptor-2 Tyrosine 1175 Signaling Controls VEGF-induced von Willebrand Factor Release from Endothelial Cells via Phospholipase C-γ1-and Protein Kinase A-dependent Pathways
    Xiong, Yan
    Huo, Yingqing
    Chen, Chao
    Zeng, Huiyan
    Lu, Xiaofan
    Wei, Chaoliang
    Ruan, Changgeng
    Zhang, Xiaoyu
    Hu, Zhenqian
    Shibuya, Masabumi
    Luo, Jincai
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (35) : 23217 - 23224
  • [46] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
  • [47] The inhibition of protein kinase CK2 activity by the CIGB-300 synthetic peptide impairs the three-dimensional cell growth, Wnt and nuclear factor κB signaling pathways in lung cancer cells
    Cirigliano, Stefano M.
    Diaz Bessone, Maria Ines
    Flumian, Carolina
    Emilio Berardi, Damian
    Perea, Silvio E.
    De Kier Joffe, Elisa Bal
    Farina, Hernan
    Todaro, Laura
    Urtreger, Alejandro
    CANCER RESEARCH, 2014, 74 (19)
  • [48] The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Qiman Zhang
    Jin Zheng
    Wen Wang
    Elyse M. Cornett
    Alan David Kaye
    Ivan Urits
    Omar Viswanath
    Fei-Long Wei
    Oncology and Therapy, 2022, 10 : 363 - 375
  • [49] The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Zhang, Qiman
    Zheng, Jin
    Wang, Wen
    Cornett, Elyse M.
    Kaye, Alan David
    Urits, Ivan
    Viswanath, Omar
    Wei, Fei-Long
    ONCOLOGY AND THERAPY, 2022, 10 (02) : 363 - 375
  • [50] Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis
    Sim, Wilson
    Jain, Sneha Rajiv
    Lim, Wen Hui
    Chin, Yip Han
    Ng, Cheng Han
    Syn, Nicholas
    Goh, Kang Shiong
    Soo, Ross
    Wang, Lingzhi
    Goh, Boon Cher
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (08) : 3567 - +